FULC Fulcrum Therapeutics Inc

Price (delayed)

$3.365

Market cap

$224.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$178.63M

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine ...

Highlights
The debt has contracted by 28% YoY and by 9% from the previous quarter
Fulcrum Therapeutics's quick ratio has increased by 25% from the previous quarter and by 20% YoY
The equity has grown by 46% YoY but it has contracted by 4.5% from the previous quarter
The revenue has plunged by 100% YoY
Fulcrum Therapeutics's gross profit has plunged by 100% YoY

Key stats

What are the main financial stats of FULC

FULC stock price

How has the Fulcrum Therapeutics stock price performed over time
Intraday
4.5%
1 week
-50.66%
1 month
-52.07%
1 year
-52.13%
YTD
-70.25%
QTD
-56.13%

Financial performance

How have Fulcrum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$86.55M
Net income
-$76.12M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
Fulcrum Therapeutics's gross profit has plunged by 100% YoY
The company's operating income fell by 2.1% QoQ

Price vs fundamentals

How does FULC's price correlate with its fundamentals

Growth

What is Fulcrum Therapeutics's growth rate over time

Valuation

What is Fulcrum Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 2.5% QoQ
FULC's P/B is 66% below its 5-year quarterly average of 1.9 and 66% below its last 4 quarters average of 1.9
The equity has grown by 46% YoY but it has contracted by 4.5% from the previous quarter
The revenue has plunged by 100% YoY

Efficiency

How efficient is Fulcrum Therapeutics business performance
FULC's return on invested capital is up by 10% since the previous quarter
Fulcrum Therapeutics's ROE has increased by 8% from the previous quarter
Fulcrum Therapeutics's ROA has increased by 8% from the previous quarter

Dividends

What is FULC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FULC.

Financial health

How did Fulcrum Therapeutics financials performed over time
FULC's total assets is up by 43% year-on-year but it is down by 5% since the previous quarter
The current ratio has grown by 25% since the previous quarter and by 20% year-on-year
The debt is 98% less than the equity
The debt to equity has dropped by 50% year-on-year
The equity has grown by 46% YoY but it has contracted by 4.5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.